-transparent.png){kind=logo}
A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcinoma.
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
March 1986,
Cancer,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
January 1985,
Journal of cancer research and clinical oncology,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
March 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
January 1984,
Cancer chemotherapy and pharmacology,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
November 1985,
Cancer,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
January 1997,
Oncology reports,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
January 1985,
Giornale italiano di chemioterapia,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
January 1983,
Oncology,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
March 1997,
Journal of the Formosan Medical Association = Taiwan yi zhi,
L Rausa, and
A Russo, and
V Gebbia, and
N Gebbia, and
N D'Alessandro, and
S Palmeri
August 1990,
Gan to kagaku ryoho. Cancer & chemotherapy,
